Skip to main content

Table 2 Clinical characteristics and outcomes according to IBD-like endoscopic pattern

From: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

Characteristic Crohn’s colitis
N = 39
Ulcerative colitis
N = 76
P value
Duration of symptoms (days, SD)
 IV steroids, n (%) 19 (61.3) 49 (75.4) 0.229
 Infliximab/vedolizumab, n (%) 12 (37.5) 29 (42.0) 0.828
 Duration from onset to recurrence (days, SD) 159 (158) 112 (118) 0.358
 Duration of steroid (days, SD) 70 (117) 60 (43) 0.529
Diarrhea grade, n (%)    0.118
 1 5 (12.8) 5 (6.6)  
 2 145 (35.9) 18 (23.7)  
 3–4 20 (51.3) 53 (69.7)  
Colitis grade, n (%)    0.201
 1 7 (17.9) 5 (6.6)  
 2 16 (41.0) 36 (47.4)  
 3–4 16 (41.0) 35 (46.1)  
High-risk endoscopic features 23 (59.0) 48 (63.2) 0.689
Active histologic inflammation 33 (84.6) 67 (88.2) 0.574
Outcomes, n (%)
 Hospitalization 30 (76.9) 65 (85.5) 0.301
 Duration of hospitalization (days) 8 (6) 8 (7) 0.855
 ICU admission 2 (5.1) 3 (3.9) 1.000
 Recurrence 15 (38.5) 16 (21.1) 0.074
 Repeat endoscopy 12 (30.8) 15 (19.7) 0.245
  1. Abbreviation: ICU intensive care unit, IV intravenous, SD standard deviation